{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:16Z","timestamp":1780038136897,"version":"3.53.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While sodium-glucose cotransporter 2 (SGLT-2) inhibitors serve as the cornerstone of therapy for diabetic kidney disease (DKD), a specific subset of patients continues to face residual risks, manifested as persistent proteinuria or declining renal function. Bailing Preparations and Huangkui Capsules are widely employed adjunctive Commercial Chinese polyherbal preparations (CCPPs). However, rigorous data differentiating their specific efficacy profiles\u2014particularly regarding anti-inflammatory targets when paired with SGLT-2 inhibitors\u2014remain undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Computerized searches were conducted in PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang Database, VIP Database, China Biomedical Literature Service System (Sinomed), and Bailing Preparation + SGLT-2i, Huangkui Capsule + SGLT-2i, and SGLT-2i monotherapy for the treatment of DKD. The search period covered from the establishment of each database to December 2025. The risk of bias was evaluated using the Cochrane RoB 2.0 tool, a network meta-analysis was performed using Stata 19.5, and the quality of evidence was assessed using the GRADE method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final analysis included 18 RCTs, involving a total of 1,564 participants. The results of the network meta-analysis showed: (1) Renal function and clinical efficacy: In terms of renal function protection, the Bailing preparation had the most significant effect in reducing serum creatinine (Scr) (MD = \u221212.31, 95% CI: \u221217.14, \u22127.48), and its Surface Under the Cumulative Ranking curve (SUCRA) probability ranking (81.8%) was the highest. The ranking results of the overall clinical efficacy (SUCRA = 79.1%) also supported this trend, with the Bailing preparation slightly superior to Huangkui Capsules. (2) Proteinuria and metabolism: Regarding proteinuria and metabolic indicators, Huangkui Capsules demonstrated unique advantages. In terms of 24-h urine protein quantification, Huangkui Capsules was the only intervention measure with a significant reduction effect (MD = \u22120.47, 95% CI: \u22120.77, \u22120.18). Additionally, its effects on fasting blood glucose (FPG) and 2-h post-meal blood glucose (2hPG) ranked the highest among all intervention measures (SUCRA values were all &amp;gt;90%). (3) Anti-inflammatory mechanism: The Bailing preparation specifically reduced systemic inflammatory markers (TNF-\u03b1 and CRP), while Huangkui Capsules reduced local inflammatory mediators IL-6. (4) Safety: The SUCRA value of Huangkui Capsules was the highest (78.6%), indicating better safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both Bailing Preparations and Huangkui Capsules can enhance the efficacy of SGLT-2i. Bailing Preparations focuses on protecting renal function by inhibiting systemic inflammation mediated by TNF\u03b1 and CRP; Huangkui Capsules focuses on regulating glucose metabolism and inhibiting local damage mediated by IL-6 to reduce proteinuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1812118","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:25Z","timestamp":1780034965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential efficacy and anti-inflammatory mechanisms of Bailing Preparations versus Huangkui Capsules combined with SGLT-2 inhibitors for diabetic kidney disease: a network meta-analysis and GRADE assessment"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Chengdu Medical College, Chengdu Pidu District People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","first-page":"126","article-title":"Effect of dapagliflozin combined with Bailing capsule in the treatment of diabetic nephropathy and its influence on inflammatory factors and renal function","volume":"19","author":"Chen","year":"2025","journal-title":"Chin. J. of Mod. Drug Appl."},{"key":"B2","first-page":"47","article-title":"Clinical observation of huang Kui capsules combined with dapagliflozin in the treatment of early diabetic nephropathy","volume":"24","author":"Chen","year":"2024","journal-title":"Pract. Clin. J. of Integr. Traditional Chin. and Biomed."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3969\/j.issn.1672-9455.2022.19.025","article-title":"Effects of Dapagliflozin combined with Bailing Capsules on urine protein and the expression of NLRP3 inflammasome in peripheral blood in patients with diabetic nephropathy","volume":"19","author":"Dang","year":"2022","journal-title":"Laboratory Med. and Clin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.16658\/j.cnki.1672-4062.2022.16.017","article-title":"Efficacy of dapagliflozin combined with Bailing Capsule in the treatment of diabetic nephropathy and its effect on renal function","volume":"25","author":"Fang","year":"2022","journal-title":"Diabetes New World"},{"key":"B4","first-page":"1447","article-title":"Clinical efficacy observation of empagliflozin combined with bailing capsules in patients with diabetic nephropathy","volume":"34","author":"Fu","year":"2023","journal-title":"Mod. Diagnosis and Treat."},{"key":"B5","first-page":"305","article-title":"Observation of the efficacy of huang Kui capsules combined with dapagliflozin in the treatment of diabetic nephropathy","volume":"39","author":"Jiang","year":"2023","journal-title":"J. of Pract. Traditional Chin. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/1744666X.2022.2045952","article-title":"Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives","volume":"18","author":"Kreiner","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B7","first-page":"355","article-title":"Efficacy analysis of bailing capsules combined with dapagliflozin in diabetic nephropathy","volume":"32","author":"Li","year":"2021","journal-title":"Lishizhen Med. and Materia Medica Res."},{"key":"B8","first-page":"98","article-title":"Research progress on the mechanism of Cordyceps sinensis in treating diabetic nephropathy","volume":"55","author":"Liu","year":"2015","journal-title":"Shandong Med. J."},{"key":"B9","first-page":"29","article-title":"Efficacy of dapagliflozin combined with bailing capsules on diabetic nephropathy and effects on renal function and glucose metabolism","volume":"27","author":"Meng","year":"2024","journal-title":"Diabetes New World Mag."},{"key":"B10","first-page":"164","article-title":"Effects of huangkui capsule combined with empagliflozin on urinary microprotein and inflammatory response in diabetic nephropathy patients","volume":"4","author":"Sun","year":"2023","journal-title":"Reflexology Rehabilitation Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. and Clin. Pract."},{"key":"B12","first-page":"18","article-title":"Clinical Observation of Huang Kui capsules combined with dapagliflozin in the treatment of early diabetic Nephropathy","volume":"24","author":"Tan","year":"2024","journal-title":"Pract. Clin. J. of Integr. Traditional Chin. and Biomed."},{"key":"B13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"Am. J. of Kidney Dis."},{"key":"B14","first-page":"141","article-title":"Clinical observation of huangkui capsule combined with dapagliflozin tablets in the treatment of diabetic kidney disease","volume":"20","author":"Wang","year":"2020","journal-title":"World Latest Med. Inf."},{"key":"B15","first-page":"731","article-title":"Efficacy of bailing capsules combined with dapagliflozin in treating diabetic nephropathy and their effects on Caspase-1 mRNA and NLRP3 inflammasome levels","volume":"24","author":"Wang","year":"2023","journal-title":"Chin. J. of Integr. Traditional and West. Nephrol."},{"key":"B30","first-page":"118","article-title":"Analysis of clinical efficacy of Bailing Tablets combined with dapagliflozin tablets in the treatment of early diabetic nephropathy","volume":"4","author":"Wang","year":"2025","journal-title":"J. Chin. Foreign Med. Res."},{"key":"B16","first-page":"228","article-title":"Effects of dioscin on renal histopathology changes and expression of TNF-\u03b1 in unilateral ureteral obstruction mice","volume":"30","author":"Wang","year":"2023","journal-title":"Chin. J. of Traditional Med. Sci. and Technol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e22017","DOI":"10.1016\/j.heliyon.2023.e22017","article-title":"The pharmacological mechanism of Abelmoschus manihot in the treatment of chronic kidney disease","volume":"9","author":"Wei","year":"2023","journal-title":"Heliyon"},{"key":"B18","first-page":"124","article-title":"Effect observation of Bailing capsule combined with dapagliflozin in the treatment of diabetic nephropathy","volume":"19","author":"Wen","year":"2025","journal-title":"Chin. J. of Mod. Drug Appl."},{"key":"B19","first-page":"23","article-title":"Clinical efficacy of huang Kui capsules combined with dapagliflozin in the treatment of diabetic nephropathy","volume":"41","author":"Yang","year":"2022","journal-title":"Inn. Mong. J. of Traditional Chin. Med."},{"key":"B20","first-page":"29","article-title":"Effect of Huangkui capsule combined with dapagliflozin on Cys-C and \u03b11-MG in patients with early diabetic nephropathy","volume":"17","author":"Yang","year":"2023","journal-title":"Chin. J. of Mod. Drug Appl."},{"key":"B21","first-page":"35","article-title":"Clinical efficacy of huangkui capsule combined with dapagliflozin in the treatment of diabetic nephropathy patients,and its impact on renal function and infl ammatory cytokine levels","volume":"43","author":"Zhang","year":"2025","journal-title":"Chinese Health Care"},{"key":"B22","first-page":"97","article-title":"Effects of bailing tablets combined with dapagliflozin on renal function in patients with diabetic nephropathy","volume":"17","author":"Zhang","year":"2024","journal-title":"Chin. J. of Clin. Ration. Drug Use"},{"key":"B23","first-page":"182","article-title":"Clinical effect of bailing tablet combined with dapagliflozin in the treatment of early diabetic nephropathy","volume":"24","author":"Zhang","year":"2021","journal-title":"Diabetes New World Mag."},{"key":"B24","first-page":"107","article-title":"Research progress on modern applications and function of bailing capsules in tonifying lungs and nourishing kidneys","volume":"40","author":"Zhang","year":"2024","journal-title":"Pharmacol. and Clin. of Chin. Materia Medica"},{"key":"B25","first-page":"267","article-title":"The synergistic cardio-renal protective effects of nonsteroidal mineralocorticoid receptor antagonist and sodium-glucose cotransporter 2 inhibitor","volume":"34","author":"Zhao","year":"2025","journal-title":"Chin. J. of Nephrol."},{"key":"B26","first-page":"105","article-title":"Analysis of the renal function improvement effect of bailing capsules combined with dapagliflozin in patients with diabetic nephropathy","volume":"9","author":"Zhao","year":"2025","journal-title":"Mod. Med. and Health Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.16068\/j.1000-1824.2025.12.021","article-title":"Observation on the efficacy of Bailing Tablets combined with dapagliflozin in treating early diabetic nephropathy","volume":"48","author":"Zhu","year":"2025","journal-title":"J. Yanbian Univ. Med. Sci."},{"key":"B27","first-page":"170","article-title":"Mechanism of action and research progress of Huangkui Capsules in treating chronic renal failure","volume":"19","author":"Zou","year":"2026","journal-title":"Chin. J. of Clin. Ration. Drug Use"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1812118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:32Z","timestamp":1780034972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1812118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":30,"alternative-id":["10.3389\/fphar.2026.1812118"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1812118","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1812118"}}